Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.
about
Ceramide: a common pathway for atherosclerosis?Inflammation in arterial diseasesLupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritisTumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytesInfliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitisClinically Apparent Arterial Thrombosis in Persons with Systemic Vasculitis.Double-stranded RNA induces shedding of the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3-TRIF-RIP1-dependent signaling: roles for dual oxidase 2- and caspase-dependent pathways.Endothelial cells, fibroblasts and vasculitisCardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.Accelerated atherosclerosis in patients with Wegener's granulomatosisVasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging.Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis.A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitisAccelerated atherosclerosis in inflammatory rheumatic diseases.Large artery stiffness and inflammation.Fatal miliary Coccidioidomycosis in a patient receiving infliximab therapy: a case report.Vascular Damage in Resistant Hypertension: TNF-Alpha Inhibition Effects on Endothelial CellsEndothelium-neutrophil interactions in ANCA-associated diseasesEffects of aging, TNF-α, and exercise training on angiotensin II-induced vasoconstriction of rat skeletal muscle arterioles.An inhibitory effect of tumor necrosis factor-alpha antagonist to gene expression in monocrotaline-induced pulmonary hypertensive rats model.Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis.Role of TNF-alpha in vascular dysfunction.Cardiovascular effects of tumour necrosis factor α antagonism in patients with acute myocardial infarction: a first in human study.TNF-α induces vascular insulin resistance via positive modulation of PTEN and decreased Akt/eNOS/NO signaling in high fat diet-fed mice.Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis.Update on the use of biologics in primary systemic vasculitides.Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors.Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.Heartsick: psychiatric and inflammatory implications of cerebromicrovascular disease.State of the art in the treatment of systemic vasculitides.Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Management of Small Vessel Vasculitides.Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement.Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets.Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Churg-strauss syndrome in the pediatric age group.Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects.Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study.[Managing comorbidities of inflammatory rheumatic diseases].
P2860
Q24630011-D213DBCD-AD32-42FE-96EE-8F69488EC8AEQ26853576-7AF96AAD-4B39-4E16-82BD-8EDB29661EFCQ28218493-88935FA6-18A8-4EC8-B1F1-2638953AC96AQ28219857-8ADF37D7-6560-4839-8D28-6B690F10D4CAQ33229786-52BE06E1-5A21-4FE6-BD22-674BC2C86D79Q33872858-287D3F8C-9990-4FB5-BB07-75FA2E98F722Q34788072-E27EF041-96F1-47DD-B80F-9C1F5E938733Q35058025-E9F9A339-106B-49BD-B9C5-95C54A7DEC3EQ35121150-F2AD9EB8-AFFD-4B6B-BF88-BB645E5D22A5Q35555500-A0989248-54FF-4FB7-8D5F-774A64B086BAQ35570406-0EC0D7C4-36E8-428C-ACFE-C2E76144B919Q35772969-EE8F1EC7-293E-453C-8B7D-27ADF9DA4F63Q35878676-60BC1FD3-555D-4B71-B304-AD4C81393F65Q35932689-4CF428AC-A1D7-48B2-A14E-B677664C425FQ36007909-00CE4D0F-4A14-4DD0-A602-B09DBD501D9BQ36054694-0C8E13E1-BAEA-4C17-935D-C29649D98B82Q36172946-7C6E5231-01B1-44F3-A575-F9B77ECD4457Q36200937-926AB326-DE7A-44BD-A4CC-BB32BEC9620EQ36366824-5ABA4D31-0CD3-4309-B972-58C2A8EA642FQ36725312-41608B15-EE0F-4169-9715-23C4E2388549Q36843060-C91D45B6-1F24-489F-8736-17C03613628AQ37050343-5817019C-81FA-4190-BCEA-3C3061FAE7A6Q37130027-192E183C-FF66-436E-8A42-D96A33DD6C8EQ37209584-65EFE5C5-F750-478D-A493-F5C3EF6333DCQ37421814-33097383-19A2-40D8-B461-E8D36A271458Q37754811-540FD536-7072-4108-B36A-14B1824A56B5Q38107072-E9C44A55-1BEA-4F3B-856E-FBABCDA78A6FQ38175430-0382B88A-BAD3-4404-AF83-6C630B69DA12Q38219438-6A7A3DCF-86F8-493B-8F1E-71559BF25556Q38263514-642E442E-42BF-4CFC-AFE3-59EA7F0B23DCQ38593867-B2C5B8D9-EEB0-42D6-81C8-853D1F6E6A47Q38631012-0F25DB7C-8166-4BEC-BD45-CACEF0B7A80AQ38818682-F7FC9F68-B5E7-4C43-8546-0A8EA0E35F28Q38946711-27C81A99-AB19-4D78-84EC-B27C83F876D2Q39038872-9021B8CC-B7DD-4DE9-BE6F-12994D768ED9Q40081220-35E60F8E-82D8-447E-8119-B03DFB5CB24DQ40617823-2A8AE98A-A470-4671-BCA3-BB274E65C605Q42844981-0060E2C2-8F3F-4E32-9512-FA29E850FA16Q43251970-1DCF36F4-1B6A-48F1-90BF-B70813583207Q44393048-D8B83E31-40B1-4B08-80BF-E55C02CFCF78
P2860
Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Infliximab improves endothelia ...... odel of vascular inflammation.
@en
Infliximab improves endothelia ...... odel of vascular inflammation.
@nl
type
label
Infliximab improves endothelia ...... odel of vascular inflammation.
@en
Infliximab improves endothelia ...... odel of vascular inflammation.
@nl
prefLabel
Infliximab improves endothelia ...... odel of vascular inflammation.
@en
Infliximab improves endothelia ...... odel of vascular inflammation.
@nl
P2093
P1433
P1476
Infliximab improves endothelia ...... odel of vascular inflammation.
@en
P2093
C M McEniery
D R W Jayne
I B Wilkinson
P304
P356
10.1161/01.CIR.0000124720.18538.DD
P407
P577
2004-03-22T00:00:00Z